← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Afasci, Inc.
Redwood City, CA
$22,325,378
Total funding
27
Grants
Funding over time
peak $2.8M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$22,325,378 · 27
By mechanism
R44$14,084,294 · 7
R43$3,917,454 · 12
R01$1,323,488 · 1
U43$982,702 · 1
R42$852,597 · 1
R41$688,936 · 3
Investigators at Afasci, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Clinical Phase I trials on an IND single molecule dual inhibitor of Cav3 channels and soluble epoxide hydrolase for treatment of neuropathic pain$1,499,931
R44 · FY2024 · NS
Clinical Phase I trials on an IND single molecule dual inhibitor of Cav3 channels and soluble epoxide hydrolase for treatment of neuropathic pain$1,499,931
R44 · FY2023 · NS
IND-enabling studies on novel Cav3 T-channel modulators for treatment of neuropathic pain$1,491,977
R44 · FY2018 · NS
IND-enabling studies on novel Cav3 T-channel modulators for treatment of neuropathic pain$1,491,584
R44 · FY2020 · NS
Development of patented tricyclic pyrones molecules for the treatment of Alzheimerâs Disease$973,076
R44 · FY2017 · AG
Development of patented tricyclic pyrones molecules for the treatment of Alzheimerâs Disease$960,706
R44 · FY2018 · AG
Development of a Next Generation Visual Performance Assessment System for Rodents$788,405
R44 · FY2019 · EY
Development of selective Cav3 channel blockers for treatment of neuropathic pain$741,690
R44 · FY2016 · NS
Development of a Next Generation Visual Performance Assessment System for Rodents$691,652
R44 · FY2020 · EY
Development of selective Cav3 channel blockers for treatment of neuropathic pain$690,517
R44 · FY2015 · NS
Nicotine delivery to rodent with lung alveolar region-targeted aerosol technology$506,122
R44 · FY2013 · DA
Development of a Novel Medication for Alcohol Use Disorder with an Active IND Dual Inhibitor of T-Type Calcium Channel and Soluble Epoxide Hydrolase$498,851
U43 · FY2024 · AA
Treat Neuropathic Pain with Dissolvable Microneedles Containing Anti-CGRP Peptide$489,887
R44 · FY2012 · DA
Treat Neuropathic Pain with Dissolvable Microneedles Containing Anti-CGRP Peptide$489,244
R44 · FY2013 · DA
Nicotine delivery to rodent with lung alveolar region-targeted aerosol technology$484,537
R44 · FY2014 · DA
Development of a Novel Medication for Alcohol Use Disorder with an Active IND Dual Inhibitor of T-Type Calcium Channel and Soluble Epoxide Hydrolase$483,851
U43 · FY2023 · AA
Development of an automated noninvasive system for sleep restriction in rodents$432,198
R42 · FY2014 · HL
Development of an automated noninvasive system for sleep restriction in rodents$420,399
R42 · FY2013 · HL
High throughput screen of behavior using piezo-imaging$374,864
R44 · FY2005 · RR
Modulation of Nociceptin/Orphanin FQ on Hypocretin Neurons in Pain and Stress$371,250
R01 · FY2008 · MH